title: Ciprostene in patients with peripheral vascular disease (PVD). An open-label, tolerance trial.
abstract: Epoprostenol (Prostacyclin) has been studied with various success in patients with peripheral vascular disease (PVD). We investigated the tolerance of a new, stable prostacyclin derivative ciprostene (9-beta-methyl carbacyclin) in 9 PVD patients. The drug was infused intravenously for 8 hours a day, once a week for 4 consecutive weeks, at a dose of 120 ng/kg/min. There were 6 men and 3 women with a mean age of 63 years (42-78). The PVD was verified by arteriography (9 patients) and by clinical findings. Patient #9 was lost to follow up after the first infusion and, consequently, was excluded from further evaluation. In patient #5 with a history of arrhythmias, the last ciprostene infusion had to be discontinued at 4.5 hours due to arrhythmias but his data were included into the evaluation. The cardiac disturbances were not judged to be ciprostene-related. Patients were followed monthly for 3 months after last infusion. Ciprostene was well tolerated although it produced adverse medical events (AMEs); most of them were rated as mild. The most frequent were those typical of prostacyclin: headache, facial flushing and warmth, body warmth, jaw pain and sleepiness. No consistent changes in blood pressure and heart rate were observed. One patient who initially had 9 ischemic ulcers underwent transmetatarsal amputation at month 4. The absolute and relative claudication time was measured by treadmill. As compared to baseline, the absolute claudication time increased significantly at week 2 and 4 of the infusion period and also at the end of month 3, but not at the end of month 4.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Upjohn Company, Kalamazoo, MI 49007.
authors.forename: O I
authors.initials: OI
authors.lastname: Linet
authors.forename: J R
authors.initials: JR
authors.lastname: Luderer
authors.forename: M
authors.initials: M
authors.lastname: Froeschke
authors.forename: S
authors.initials: S
authors.lastname: Welch
authors.forename: C M
authors.initials: CM
authors.lastname: Metzler
authors.forename: S M
authors.initials: SM
authors.lastname: Eckert
mesh_terms: D000328:Adult; D000368:Aged; D011464:Epoprostenol / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000031:analogs & derivatives; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D014652:Vascular Diseases / Q000188:drug therapy*
chemical_list: D011464:Epoprostenol; C045329:ciprostene